



24 February 2025

DR TOM TAKUBO TO RETIRE, JONATHAN ADAMS APPOINTED TO RESPIRI BOARD

Respiri Limited (ASX:RSH; OTCQB:RSHUF) (**Respiri**) notes that Dr Tom Takubo will retire today as Director of Respiri. The Board of Respiri would like to thank Dr Takubo for his insights and contribution to Respiri during his tenure as a Director of the Company.

In response to Dr Takubo retiring from the Board, Respiri is pleased to announce the appointment of Mr Jonathan Adams to the Board of Directors as Non-Executive Director effective today.

Jonathan Adams currently serves as an Investment Director at Mt. Vernon Investments, LP. Mr. Adams joined Mt. Vernon Investments in 2007 and is primarily responsible for sourcing, structuring, and executing private equity and venture capital investments across direct, co-investments, and select fund investments. Prior to joining Mt. Vernon Investments, Mr. Adams was an accountant at PricewaterhouseCoopers. Mr. Adams holds both a BBA and an MPA from The University of Texas at Austin. Mr. Adams is a CFA® charterholder and a Certified Public Accountant in the State of Texas.

Mr. Adams served as Chairman of the Board for Orb Health, Inc. and also serves as a Board Director for TTI Acquisition, LLC, parent company of TTI Sports International. Mr. Adams serves as a Board Observer for multiple portfolio company investments of Mt. Vernon Investments. Mr. Adams resides in Dallas, TX with his wife and family.

Respiri Chairman, Mr Nicholas Smedley commented:

"The Board of Respiri is delighted to welcome Jonathan Adams, who in his role with Mt Vernon and as Chairman of Orb Health, the complementary healthcare business recently acquired by Respiri will enhance the Board's capabilities. His extensive experience in U.S. capital and investment markets, combined with his healthcare expertise and Respiri/Orb business understanding, will strengthen our US growth strategy, governance and enhance shareholder value."

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited – A Revolutionary Remote Healthcare Solutions Provider

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is leading the charge in transforming healthcare delivery in the US. As an innovator in medical devices and MedTech, we combine state-of-the-art technologies with unparalleled clinical expertise. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders. Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and



superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.respiri.co/au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us> or for [wheezo®](#)

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.

wheezo® is a registered trademark of Respiri Limited